본문 바로가기
intron logo

logo

  • About us
    • BUSINESS
    • R&BD HISTORY
    • OUR EXPERTISE
    • OUR PEOPLE
    • INSIDE iNtRON
  • Platform
    • TECHNOLOGY OVERVIEW
    • PHAGERIARUS®
    • PHAGERUS®
    • PHAGERIA®
    • itLysin®
    • im-MucoDr®
  • AD / BC
    • AD / BC
    • Triangle Hypothesis
  • B.E.C. Project
    • B. E. C. PROJECT
  • Partnering
    • PARTNERING
    • CONTACT
  • Address.

    iNtODEWORLD
    1500 District Avenue,
    Suite 2097, Burlington, MA 01803, USA

    iNtRON Biotechnology
    Suite 701~704, 137, Sagimakgol-ro, Jungwon-gu,
    Seongnam-si, Gyeonggi-do, Republic of Korea

  • Email.

    partner@intron.co.kr

  • The Head of Lifetech Research Center, Dr. Kang(CFO), Won a President C..

    02 January,2020
  • Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Sup..

    20 November,2018
  • First Endolysin-based Orphan Drug Designated by US FDA

    29 June,2018
  • Nightmare bacteria’ are trying to spread in the U.S.

    10 April,2018
  • Management of multi-drug resistant organisms in healthcare settings

    26 March,2018
  • AMR Industry Alliance Progress Report Published – SAL200 as “Notable T..

    18 January,2018
  • N-Rephasin® SAL200 Phase 1b Multiple Ascending Dose (MAD) Study Initia..

    18 January,2018
  • Endolysin Based Treatment for Anthrax in Nature-Scientific Reports

    17 January,2018
  • iNtRON’s Presentation at 2017 Antibiotics and Antibiotic Resistance Co..

    08 December,2017
  • FDA Bacteriophage Workshop

    08 December,2017
1 2 3 4
  • Address.
    iNtODEWORLD
    1500 District Avenue,
    Suite 2097, Burlington, MA 01803, USA
    iNtRON Biotechnology
    Suite 701~704, 137, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
  • Email.
    partner@intron.co.kr

(C) 2022. iNtODEWORLD. Inc. All rights reserved.